Tullis — Full Portfolio
10 tracked investments · listed companies and verified rows first
HealthtechCarlsbad, US
Terry M. Rich(Executive Officer, Director)Craig Hunsaker(Executive Officer)John Allen(Executive Officer)Jeffrey Black(Executive Officer)Patrick S. Miles(Executive Officer, Director)
BoardMortimer Berkowitz III(Director)
Board seatJames L. L. Tullis· per SEC Form D · $168M raise · filed Dec 2020
electroCore develops non-invasive vagus nerve stimulation (nVNS) medical devices, marketed as gammaCore, to treat patients suffering from pain and chronic conditions.
BiotechDigital HealthHardwareHealthtechMedical DevicesBasking Ridge, US
JP Errico(Executive Officer)Brian Posner(Executive Officer)Daniel S. Goldberger(Executive Officer, Director)Peter Staats(Director)Frank Amato(Executive Officer)
BoardTrevor Moody(Director)
Board seatJames L.L. TullisJames Tullis· per SEC Form D · $1.7M raise · filed Apr 2020
Co-investorsFoothill VenturesTullis Health Investors
Exagen develops diagnostic and monitoring tests for autoimmune diseases, including tools to distinguish connective tissue disease and assess lupus prognosis and progression.
BiotechDigital HealthHealthtechMedical DevicesVista, US
Thierry Dervieux(Executive Officer)Wendy Swedick(Executive Officer)Fortunato R. Rocca(Executive Officer, Director)Sam Riccitelli(Director)Curt LaBelle(Director)Michael Walsh(Director)
Board seatJames L.L. Tullis· per SEC Form D · $3M raise · filed Jul 2015
Co-investorsCottonwood Technology FundEPIC VENTURESH.I.G. CapitalH.I.G. HealthBridge PartnersSun Mountain CapitalTullis Health Investors
Hyperion DeFi is a U.S.
BiotechCrypto & Web3FintechHealthtechLaguna Hills, US
Michael Rowe(Executive Officer, Director)Hyunsu Jung(Chief Executive Officer)BARRY BUTLER(Executive Officer)David(Chief Financial Officer)TSONTCHO IANCHULEV(Executive Officer, Director)
Board seatCurt LaBelle· per SEC Form D · $6M raise · filed Apr 2020
Co-investorsEshelman Ventures, LLC
BiotechSherborn, US
MARC ODRICH(Director)JONATHAN TALAMO(Director)EDWARD PARSONS(Executive Officer)SUSAN MACDONALD(Director)MICHAEL WEBB(Executive Officer, Director)
Board seatCurt Labelle· per SEC Form D · $50.3M raise · filed Oct 2022
Menlo Park, US
Fred St. Goar(Director)Shacey Petrovic(Director)Anne Morrissey(Executive Officer, Director)Phyllis Whiteley(Director)
Board seatCurt LaBelle· per SEC Form D · $12.6M raise · filed Aug 2018
Novocuff is a medical device company developing the Novocuff Cervical Control System, an investigational device aimed at improving outcomes for pregnancies affected by preterm prelabor rupture of membranes (PPROM) or cervical shortening.
FemTechHealthtechMedical DevicesMountain View, US
Donald Lee(Executive Officer)Amelia Degenkolb(Executive Officer, Director)
BoardLilly DeSouza Burr(Director)Rebecca Shmukler(Director)inShacey Petrovic(Director)
Board seatCurt LaBelle· per SEC Form D · $28M raise · filed Jul 2024
Co-investorsForeground CapitalLaerdal Million Lives Fund
HealthtechHunt Valley, US
Mark D'Addato(CFO and Secretary)Eugene Cattarina(CEO)Richard O'Brien(Director)Rob Snow(Director)Curt LaBelle(Executive Officer, Director)Tsontcho Ianchulev(Director)
Board seatJames L.L. Tullis· per SEC Form D · $5.9M raise · filed Jan 2018
San Diego, US
Floyd Miller(Executive Officer, Director)
BoardMichael Sennott(Director)Terrance S. Meehan(Director)
Board seatJames L.L. Tullis· per SEC Form D · $3M raise · filed Apr 2019
Vedanta Biosciences is a clinical-stage biotech developing Live Biotherapeutic Products (LBP) based on defined consortia of bacteria to treat serious gastrointestinal diseases, with an initial focus on preventing recurrent Clostridium difficile infection.
BiotechHealthtechCambridge, US
Bernat Olle(Executive Officer, Director)Daniel Couto(Executive Officer)Mark Mullikin(Executive Officer)Jeffrey Silber(Executive Officer)Christopher Viehbacher(Director)
BoardJohn LaMattina(Director)
Board seatCurt LaBelle· per SEC Form D · $118.5M raise · filed Aug 2024
Co-investorsAMR Action FundK2 HealthVenturesSalica InvestmentsBNP ParibasBNP Paribas Asset Management Europe
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.